Nuclear receptors, inflammation, and liver disease: Insights for cholestatic and fatty liver diseases

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 4, 2010, Pages 473-478

  Arrese, M ^a   Karpen, S J ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 ETHYLCHENODEOXYCHOLIC ACID; CELL NUCLEUS RECEPTOR; CHENODEOXYCHOLIC ACID DERIVATIVE; CONSTITUTIVE ANDROSTANE RECEPTOR; FARNESOID X RECEPTOR; FIBRIC ACID DERIVATIVE; HEPATOCYTE NUCLEAR FACTOR 4 ALPHA; HORMONE RECEPTOR BLOCKING AGENT; INT 747; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHENOBARBITAL; PIOGLITAZONE; PREGNANE X RECEPTOR; RIFAMPICIN; ROSIGLITAZONE; UNCLASSIFIED DRUG;

CLINICAL STUDY; CLINICAL TRIAL; EXPERIMENTAL STUDY; HUMAN; INFLAMMATION; INTERVENTION STUDY; INTRAHEPATIC CHOLESTASIS; INTROSPECTION; LIPOGENESIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; WEIGHT GAIN;

ANIMALS; CHOLESTASIS; DRUG DELIVERY SYSTEMS; FATTY LIVER; HUMANS; INFLAMMATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 77949875356     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.2     Document Type: Review

References (41)

1. Medzhitov, R. Origin and physiological roles of infammation. Nature 454, 428-435 (2008).
2. Dasarathy, S. Infammation and liver. JPEN J. Parenter. Enteral Nutr. 32, 660-666 (2008).
3. Ramadori, G., Moriconi, F., Malik, I. & Dudas, J. Physiology and pathophysiology of liver infammation, damage and repair. J. Physiol. Pharmacol. 59(Suppl 1), 107-117 (2008).
4. Iredale, J. Defning therapeutic targets for liver fbrosis: exploiting the biology of infammation and repair. Pharmacol. Res. 58, 129-136 (2008).
5. Downes, M. & Liddle, C. Look who's talking: nuclear receptors in the liver and gastrointestinal tract. Cell Metab. 7, 195-199 (2008).
6. Bensinger, S.J. & Tontonoz, P. Integration of metabolism and infammation by lipid-activated nuclear receptors. Nature 454, 470-477 (2008).
7. Karpen, S.J. Nuclear receptor regulation of hepatic function. J. Hepatol. 36, 832-850 (2002).
8. Gronemeyer, H., Gustafsson, J.A. & Laudet, V. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 3, 950-964 (2004).
9. Mulder, J., Karpen, S.J., Tietge, U.J. & Kuipers, F. Nuclear receptors: mediators and modifers of infammation-induced cholestasis. Front. Biosci. 14, 2599-2630 (2009).
10. Geier, A., Fickert, P. & Trauner, M. Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3, 574-585 (2006).
11. Wagner, M., Zollner, G. & Trauner, M. New molecular insights into the mechanisms of cholestasis. J. Hepatol. 51, 565-580 (2009).
12. Zollner, G. & Trauner, M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br. J. Pharmacol. 156, 7-27 (2009).
13. Kosters, A. & Karpen, S.J. Bile acid transporters in health and disease. Xenobiotica. 38, 1043-1071 (2008).
14. Ghose, R., Zimmerman, T.L., Thevananther, S. & Karpen, S.J. Endotoxin leads to rapid subcellular re-localization of hepatic RXRα: A novel mechanism for reduced hepatic gene expression in infammation. Nucl. Recept. 2, 4 (2004).
15. Geier, A. et al. Hepatocyte nuclear factor-4α is a central transactivator of the mouse Ntcp gene. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G226-G233 (2008).
16. Donner, M.G., Warskulat, U., Saha, N. & Häussinger, D. Enhanced expression of basolateral multidrug resistance protein isoforms Mrp3 and Mrp5 in rat liver by LPS. Biol. Chem. 385, 331-339 (2004).
17. Geier, A., Wagner, M., Dietrich, C.G. & Trauner, M. Principles of hepatic organic anion transporter regulation during cholestasis, infammation and liver regeneration. Biochim. Biophys. Acta 1773, 283-308 (2007).
18. Wang, Y.D., Chen, W.D., Wang, M., Yu, D., Forman, B.M. & Huang, W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic infammatory response. Hepatology 48, 1632-1643 (2008).
19. Wagner, M., Zollner, G. & Trauner, M. Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic infammation. Hepatology 48, 1383-1386 (2008).
20. Utzschneider, K.M. & Kahn, S.E. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 91, 4753-4761 (2006).
21. Anderson, N. & Borlak, J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol. Rev. 60, 311-357 (2008).
22. Matteoni, C.A., Younossi, Z.M., Gramlich, T., Boparai, N., Liu, Y.C. & McCullough, A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116, 1413-1419 (1999).
23. Bugianesi, E. et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123, 134-140 (2002).
24. Tilg, H. & Moschen, A.R. Insulin resistance, infammation, and non-alcoholic fatty liver disease. Trends Endocrinol. Metab. 19, 371-379 (2008).
25. Capeau, J. Insulin resistance and steatosis in humans. Diabetes Metab. 34, 649-657 (2008).
26. Marra, F. & Bertolani, C. Adipokines in liver diseases. Hepatology 50, 957-969 (2009).
27. Alkhouri, N. et al. Adipocyte apoptosis: A link between obesity, insulin resistance and hepatic steatosis. J. Biol. Chem 285, 3428-3438 (2010).
28. Trauner, M., Arrese, M. & Wagner, M. Fatty liver and lipotoxicity. Biochim. Biophys. Acta (2009); e-pub ahead of print 24 October 2009.
29. Marra, F. Nuclear factor-kappaB inhibition and non-alcoholic steatohepatitis: infammation as a target for therapy. Gut 57, 570-572 (2008).
30. Kodama, Y. & Brenner, D.A. c-Jun N-terminal kinase signaling in the pathogenesis of nonalcoholic fatty liver disease: Multiple roles in multiple steps. Hepatology 49, 6-8 (2009)
31. Yki-Järvinen, H. Thiazolidinediones. N. Engl. J. Med. 351, 1106-1118 (2004).
32. Karpen, S.J., & Trauner, M. The new therapeutic frontier-nuclear receptors and the liver. J. Hepatol. (in press).
33. Cariou, B. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis. Diabetes Metab. 34, 685-691 (2008).
34. Kakizaki, S., Takizawa, D., Tojima, H., Yamazaki, Y. & Mori, M. Xenobiotic-Sensing Nuclear Receptors CAR and PXR as Drug Targets in Cholestatic Liver Disease. Curr. Drug Targets 10, 1184-1193 (2009).
35. Dong, B. et al. Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc. Natl. Acad. Sci. U.S.A. 106, 18831-18836 (2009).
36. George, J. & Liddle, C. Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Mol. Pharm. 5, 49-59 (2008).
37. ClinicalTrials.gov. Study of INT-747 as Monotherapy in Patients With PBC http://clinicaltrials.gov (2007).
38. Ali, R. & Cusi, K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann. Med. 41, 265-278 (2009).
39. ClinicalTrials.gov. Study of INT-747 in Patients With Diabetes and Presumed NAFLD http://clinicaltrials.gov (2007).
40. ClinicalTrials.gov. Study of INT 747 in Combination With URSO in Patients With PBC http://clinicaltrials.gov (2007).
41. Sanyal, A.J. et al. A new therapy for nonalcoholic fatty liver disease and diabetes? INT-747-the frst FXR hepatic therapeutic study. Hepatology 50, 389A (2009).